Titan Pharmaceuticals (Titan Pharmaceuticals) Float Percentage Of Total Shares Outstanding : 81.60% (As of Jun. 02, 2024)

View and export this data going back to 1996. Start your Free Trial

What is Titan Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Titan Pharmaceuticals's float shares is 0.74 Mil. Titan Pharmaceuticals's total shares outstanding is 0.91 Mil. Titan Pharmaceuticals's float percentage of total shares outstanding is 81.60%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Titan Pharmaceuticals's Insider Ownership is 21.06%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Titan Pharmaceuticals's Institutional Ownership is 0.62%.

Titan Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Titan Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.74	/	0.91
	=	81.60%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Titan Pharmaceuticals (Titan Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (NAS:TTNP) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

TN70:Germany

Address

400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080

Website

https://www.titanpharm.com

Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.

Executives

Seow Gim Shen	10 percent owner	NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
Sire Group Ltd.	10 percent owner	NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
David Natan	director	11190 BISCAYNE BLVD, MIAMI FL 33181
Matthew Charles Mcmurdo	director	1047 SEWARD AVE., WESTFIELD NJ 07090
Peter Louis Chasey	director	3295 N. FORT APACHE ROAD, STE. 110, LAS VEGAS NV 89129
Eric Howard Greenberg	director	710 CARLYLE ST, WOODMERE NY 11598
Avraham Ben-tzvi	director	44 ZAYT SHEMEN ST., FLAT 4, EFRAT L3 9045544
Katherine Beebe	director, officer: President and COO	400 OYSTER POINT BLVD, SUITE 505, SOUTH SAN FRANCISCO CA 94080
Choon Hau Choong	10 percent owner	NO. 23 LORONG TERUBONG RIA 2,, PAYA TERUBONG, GEORGE TOWN N8 11060
David E. Lazar	director, 10 percent owner, officer: Chief Executive Officer	VILLA 1, 14-43RD STREET, JUMEIRAH 2, DUBAI C0 00000
Activist Investing Llc	other: Member of 10% owner group	1185 AVENUE OF THE AMERICAS, 3RD FLOOR., NEW YORK NY 10036
Joseph A Akers	director	630 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10111
James R Mcnab	director	C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Marc Rubin	director, officer: Executive Chairman	C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Dane Hallberg	officer: See Remarks	400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO CA 94080